Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
Investing.com -- Shares of Blueprint Medicines Corp (NASDAQ:BPMC) surged 26.5% following the announcement that the biopharmaceutical company will be acquired by Sanofi (NASDAQ:SNY) in a deal valued at approximately $9.5 billion. The acquisition is aimed at expanding Sanofi’s portfolio in rare immunological diseases and adding an early-stage pipeline in immunology.
Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025. Additionally, Blueprint shareholders are set to receive a non-tradeable contingent value right (CVR), which could lead to further payments based on future milestones for BLU-808, an investigational treatment in Blueprint’s pipeline.
The acquisition will bring Ayvakit/Ayvakyt, the only approved medication for advanced and indolent systemic mastocytosis (ASM & ISM), into Sanofi’s immunology portfolio. Ayvakit achieved net revenues of nearly $150 million in the first quarter of 2025, showing a growth of over 60% compared to the same quarter last year. The transaction also includes elenestinib, a next-generation treatment for SM currently in a phase 2/3 study, and BLU-808, a promising oral wild-type KIT inhibitor.
Blueprint’s CEO, Kate Haviland, expressed pride in the company’s innovations and collaborations that have improved patient outcomes. She anticipates that the merger with Sanofi will accelerate their mission to deliver life-changing medicines to more patients globally.
Sanofi plans to finance the acquisition with available cash and proceeds from new debt, stating that the deal will be accretive to gross margin and EPS after 2026. The acquisition is expected to close in the third quarter of 2025, pending regulatory approvals and the tender of a majority of Blueprint’s outstanding shares.
The market’s positive response to the acquisition reflects investor confidence in the strategic value of the deal for Sanofi’s growth in the rare disease and immunology sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.